IGF-LR3

ACTIVE MALIGNANCY — ABSOLUTE CONTRAINDICATION FOR THE MOST SPECIFIC REASON IN THIS BOOK

For most compounds in this book, the active malignancy contraindication stems from growth factor concerns that are theoretical or secondary. For IGF-LR3, this contraindication is grounded in the most direct oncological mechanism available: IGF-1R activation promotes tumor cell survival, proliferation, and resistance to apoptosis in a substantial proportion of human cancers. IGF-LR3 was designed to produce maximum, unregulated, sustained IGF-1R activation. In the oncology field, blocking this pathway is an active therapeutic target. Cancer histologies with documented IGF-1R dependence or overexpression include: breast cancer (especially ER+ subtypes and triple-negative); prostate cancer; colorectal cancer; lung cancer (non-small cell); hepatocellular carcinoma; multiple myeloma; Ewing sarcoma and other pediatric sarcomas. The IGFBP system that IGF-LR3 bypasses normally prevents supraphysiological free IGF-1 from reaching tumor cells. IGF-LR3 eliminates this protection. Anyone with active malignancy: absolute contraindication. Anyone with a history of malignancy with known IGF-1R sensitivity: absolute contraindication pending oncologist consultation. Anyone with strong family history or elevated cancer risk: elevated caution warranted.

Hypoglycemia is the most acutely dangerous side effect in day-to-day IGF-LR3 use. The mechanism: IGF-1R cross-reactivity with the insulin receptor drives glucose uptake into muscle and adipose cells; this glucose-lowering effect occurs regardless of food intake. At 20-50 mcg/day (typical community starting doses), hypoglycemia risk is dose-dependent and most pronounced in the fasted state. Community-reported hypoglycemia symptoms: dizziness, confusion, shakiness, and in severe cases, loss of consciousness. The practical management protocol: (1) never inject in a fasted state; (2) inject post-workout, when glucose has been consumed and blood sugar is already being managed by workout context; (3) eat carbohydrates within 30 minutes of injection; (4) keep fast-acting glucose (tablets, juice) accessible for the first few weeks; (5) start at 20 mcg to assess individual sensitivity before escalating. The hypoglycemia risk is manageable but requires active management — it should not be dismissed as a minor inconvenience.

Acromegaly — the disease state caused by excess GH or IGF-1 — produces characteristic physical changes: jaw enlargement; frontal bossing; hand and foot growth; thickening of soft tissues; internal organ enlargement (organomegaly). These changes result from sustained supraphysiological IGF-1R stimulation in bone and soft tissues. IGF-LR3 produces continuous IGF-1R stimulation across all tissues with IGF-1R expression. At community doses (20-100 mcg/day), the absolute IGF-1R stimulation is lower than frank acromegaly — but the duration and continuity is unusual: typical cycled protocols run 4-6 weeks of daily stimulation without the normal IGFBP-mediated pulsatility. Community reports of hand/foot tingling (early neurological effect from soft tissue changes), mild jaw changes, and gut distension (attributed to intestinal smooth muscle IGF-1R stimulation) suggest that even short cycles produce measurable off-target IGF-1R activation in non-muscle tissues. Cycling limits are partly motivated by avoiding progressive organ effects.

Prolonged continuous IGF-1R activation leads to receptor downregulation via ligand-induced internalization, ubiquitin-mediated degradation, and reduced receptor expression — the same mechanism that limits efficacy of any continuously administered receptor agonist. Community cycling of 4-6 weeks on, 4-6 weeks off is partly motivated by allowing IGF-1R density to return to baseline, restoring sensitivity for the next cycle. At doses above 50-60 mcg/day, the relationship between dose and perceived benefit becomes non-linear — users consistently report diminishing marginal returns, consistent with progressive receptor saturation and internalization. This is the community's empirical observation of a well-characterized receptor biology phenomenon.

Sustained supraphysiological IGF-1R signaling through IRS-1 phosphorylation can produce downstream insulin resistance via serine phosphorylation of IRS-1 (a negative regulatory mechanism that blunts both IGF-1R and IR signaling). Extended cycles — particularly above 6 weeks — are associated with progressive insulin resistance in community reports, manifesting as reduced glucose tolerance, elevated fasting blood sugar, and increased insulin requirements. This insulin resistance is typically reversible upon discontinuation but may take weeks to fully resolve. The combination of IGF-LR3 with insulin is particularly high-risk and represents a dangerous stacking practice.

IGF-LR3 has specific stability requirements that make quality control more critical than for most peptides in this book. The molecule is sensitive to pH (optimal stability at slightly acidic pH, 3-5); stable at acidic pH but degrades more rapidly at physiological pH; temperature-sensitive (lyophilized powder should be stored at -20°C; reconstituted solution at 4°C and used within 2-4 weeks). Importantly: bacteriostatic water reconstitution is not optimal — dilute acetic acid (0.1%) is preferable for stability at room temperature storage. The 83-amino acid structure is larger than most community-used peptides and more susceptible to degradation from agitation, temperature excursion, and improper storage. Degraded IGF-LR3 will not produce the expected pharmacological effect; determining whether a failed response is due to degraded product or individual resistance requires quality assessment at the vendor level.

IGF-1 (native): 70 amino acids. IGF-LR3: 83 amino acids. The modifications: (1) Position 3 substitution: In native IGF-1, glutamic acid (Glu, a negatively charged amino acid) occupies position 3 in the N-terminal domain. This contributes to the electrostatic and geometric complementarity required for IGFBP-3 and IGFBP-5 binding, the two most abundant circulating binding proteins. Substituting arginine (Arg, a positively charged amino acid with a bulkier side chain) disrupts this interaction. The Arg-3 modification is the primary determinant of IGFBP binding reduction. (2) 13-amino acid N-terminal extension (MFPAMPLLSLFVN): This extension adds additional steric bulk at the N-terminus of the molecule, further disrupting the binding geometry required for IGFBP interaction. The N-terminal domain of IGF-1 is partially shared between the binding sites for IGFBP and IGF-1R, but the extensions and substitutions were engineered to disrupt IGFBP binding while preserving IGF-1R interaction.

The six IGF binding proteins (IGFBPs 1-6) constitute a sophisticated bioavailability regulatory layer for the IGF system. Each IGFBP has different tissue expression patterns, regulation by hormones and nutrients, and interactions with specific tissues and cell types. IGFBP-3, the most abundant (accounts for >80% of circulating IGF-1 binding), forms a ternary complex with IGF-1 and acid-labile subunit (ALS) that extends the half-life of IGF-1 from minutes to hours — acting as a reservoir and slow-release depot. IGFBP-1 and IGFBP-2 fluctuate with nutritional status and regulate IGF-1 access to liver and kidney. IGFBP-4 and -5 may present IGF-1 to specific local receptors or inhibit access depending on context. The net effect: the IGFBP system is a tissue-specific, hormonally regulated, nutritionally responsive system for controlling exactly how much free IGF-1 reaches IGF-1R in each tissue at each moment. By eliminating IGFBP binding, IGF-LR3 eliminates this regulation entirely — all tissues receive IGF-LR3 in proportion to blood flow and local IGF-1R expression, with no regulatory modulation.

Parameter

Native IGF-1 (bound)

Free Native IGF-1

IGF-LR3

IGFBP binding

~99% bound

~1% free

<1% bound; >99% free

Effective half-life

~12-15 hours (as ternary complex)

~10-20 minutes (unbound)

~20-30 hours

IGF-1R-accessible fraction

~1% of total

All

~100% of total

Receptor potency per unit dose

Low (binding protein sequestration)

High

~100x higher effective potency vs total IGF-1

Tissue distribution

IGFBP-regulated, tissue-specific

Non-specific; brief

Non-specific; sustained (~20-30 hr)

Dosing frequency

—

Continuous infusion needed for sustained effect

Once daily feasible

An important clarification on the '100-fold higher potency' claim: IGF-LR3 does not have greater IGF-1R binding affinity than native IGF-1 — both have comparable receptor affinity (in fact, some in vitro data show LR3 slightly lower). The ~100-fold potency advantage is entirely pharmacokinetic: it comes from the 100x higher free-ligand fraction available to bind receptors, not from superior receptor interaction. This distinction matters for understanding dose-response relationships and the ceiling of achievable effect.

IGF-1 receptor (IGF-1R) is a transmembrane receptor tyrosine kinase with structural homology to the insulin receptor (IR). Structure: heterotetrameric — two extracellular α-subunits (ligand binding) linked by disulfide bonds to two transmembrane β-subunits (kinase activity). Expressed on virtually every cell type in the body: skeletal muscle, cardiac muscle, liver, adipose tissue, bone, neurons, and critically — on most tumor cell lines. IGF-LR3 binding to IGF-1R → ligand-induced conformational change → trans-autophosphorylation of β-subunit kinase domains → activation of intrinsic tyrosine kinase → phosphorylation of insulin receptor substrate-1 (IRS-1) and Shc adaptor proteins → activation of two primary downstream cascades.

IRS-1 phosphorylation → PI3K (phosphatidylinositol 3-kinase) → PIP2 → PIP3 → Akt (protein kinase B) → mTORC1 activation. mTORC1 phosphorylates p70S6K (ribosomal protein S6 kinase) and 4E-BP1 (eukaryotic initiation factor 4E-binding protein) → increased ribosome biogenesis and cap-dependent mRNA translation → increased protein synthesis rate. mTORC1 activation is also a fundamental driver of muscle protein synthesis in response to resistance exercise and amino acid availability. This is the core anabolic pathway downstream of IGF-1R that the community is targeting. It is well-characterized, universally accepted, and applies to all IGF-1R agonists including native IGF-1 and IGF-LR3.

Shc adaptor → Grb2/SOS → Ras → Raf → MEK → ERK1/2 (extracellular signal-regulated kinase). ERK1/2 promotes: transcription factor activation (c-Fos, c-Jun, Elk-1); satellite cell proliferation; myoblast differentiation; cell cycle progression. Satellite cells are muscle stem cells that contribute to hypertrophy (by donating nuclei to existing fibers) and potentially hyperplasia (formation of new muscle fibers). IGF-1R-mediated satellite cell activation through the MAPK pathway is the mechanistic basis for the community's belief that IGF-LR3 might produce 'new muscle fibers' (hyperplasia) rather than just enlargement of existing ones — though the evidence for IGF-1 or IGF-LR3-induced human muscle hyperplasia is not established.

THE ANTI-APOPTOTIC PATHWAY — WHY THIS MATTERS FOR THE CANCER RISK

One of IGF-1R's most important downstream effects is suppression of apoptosis (programmed cell death). The PI3K/Akt pathway activates several anti-apoptotic mechanisms: phosphorylation and inactivation of BAD (pro-apoptotic BCL-2 family member); activation of NF-κB (anti-apoptotic transcription factor); phosphorylation and inactivation of FOXO transcription factors (which otherwise promote pro-apoptotic gene expression); activation of MDM2 (which promotes p53 degradation — p53 being the primary tumor suppressor that triggers apoptosis in response to DNA damage). In normal physiology, IGF-1R's anti-apoptotic signaling is balanced by other cellular checkpoints. In malignant cells: IGF-1R overexpression or constitutive pathway activation provides a survival advantage — cancer cells with active IGF-1R signaling are better at evading the apoptosis that would otherwise eliminate them. Anti-IGF-1R therapies in oncology are specifically designed to restore this apoptotic sensitivity. IGF-LR3 continuously activates the exact pathway that these therapies attempt to block.

IGF-1R and insulin receptor (IR) share ~70% sequence homology in the kinase domain and can form hybrid receptors. IGF-1 (and IGF-LR3) has approximately 1-5% the potency of insulin at IR — meaning it can produce insulin-like glucose-lowering effects at sufficiently high doses. In community use at 20-50 mcg/day, this cross-reactivity translates to a meaningful hypoglycemia risk, particularly in the fasted state. The insulin-like glucose uptake into muscle cells that accompanies IGF-1R stimulation is not entirely separable from IR cross-reactivity, and both contribute to the glucose-lowering that necessitates carbohydrate co-administration with IGF-LR3 injections.

The IGF-1/IGF-1R anabolic system has been extensively characterized in animal models. IGF-1 overexpression in transgenic mice: prevents age-related muscle atrophy; increases muscle mass significantly above genetic limits; accelerates regeneration from injury (Barton-Davis et al., 1998; Musaro et al., 2001). Local IGF-1 infusion in animal models: increases muscle protein synthesis and fiber cross-sectional area. IGF-LR3 specifically: Tomas et al. (1996) demonstrated 1.5-2x greater potency than native IGF-1 in catabolic sheep models. Multiple cell culture systems: IGF-LR3 reliably activates mTOR, ERK, and anti-apoptotic pathways in myocyte cultures at very low concentrations (nanomolar range). This preclinical evidence is genuinely strong — the mechanisms are not in dispute. The translation to human body composition is where the evidence gap exists.

Mecasermin (Increlex, native recombinant IGF-1) is FDA-approved for severe primary IGF-1 deficiency (Laron syndrome — a condition where GH receptor mutations prevent normal IGF-1 production). In GH-deficient or IGF-1-deficient patients, replacing IGF-1 improves muscle mass, reduces fat mass, and improves metabolic markers. This is the most relevant human evidence — but it applies to a deficient population being restored to normal, not to healthy athletes seeking supraphysiological anabolism. IGF-1 supplementation in healthy, IGF-1-normal adults produces much smaller and less consistent effects. There are no controlled trials of native IGF-1 for body composition in healthy adults with normal IGF-1 status that demonstrate meaningful muscle hypertrophy.

No controlled human clinical trial has evaluated IGF-LR3 for body composition, muscle hypertrophy, or fat loss in healthy adults. No dose-response safety study in healthy humans has been completed. No pharmacokinetic study in healthy human subjects is publicly available. The human evidence for IGF-LR3 body composition effects is: (1) mechanistic extrapolation from the IGF-1R anabolic pathways; (2) animal model data; (3) community observational reports. Grade E for body composition claims — community consensus without controlled human evidence.

The population-level relationship between IGF-1 and cancer is one of the more studied epidemiological associations in oncology. Key findings: Higher circulating IGF-1 levels are associated with increased risk of breast, prostate, and colorectal cancer in multiple large prospective cohort studies. A meta-analysis (Renehan et al., Lancet 2004, updated 2006): found statistically significant associations between higher IGF-1 levels and colorectal cancer (odds ratio 1.49), premenopausal breast cancer (OR 1.65), and prostate cancer (OR 1.49) in men under 60. The relationship is not linear and not fully characterized — these are population-level associations. They do not prove that IGF-LR3 at community doses causes cancer. But they establish a biological signal that makes the cancer risk of continuous supraphysiological IGF-1R stimulation a genuine, not theoretical-only, concern.

Claim

Grade

Evidence

Honest Assessment

IGF-1R → PI3K/Akt/mTOR → muscle protein synthesis

A

Established cellular/molecular biology; universally replicated

The pathway is real; applies to any IGF-1R agonist

IGF-LR3 reduces IGFBP binding >100-fold vs native IGF-1

A

Francis et al. 1992; multiple independent confirmations

The pharmacokinetic property is established

t1/2 ~20-30 hours vs ~10-15 min for free native IGF-1

A

Multiple pharmacokinetic studies in animal and cell culture models

Well-established

Satellite cell activation and proliferation (preclinical)

B-C

Animal models; cell culture; IGF-1 overexpression transgenics

Robust preclinical; human muscle hyperplasia not established

Body composition improvement: healthy adults

E

No controlled human trial; community observational only

Grade E — mechanism plausible; outcome evidence absent

Hypoglycemia risk from insulin receptor cross-reactivity

B

Mechanism established; community reports; dose-dependent

Real risk; requires management protocol

IGF-1R overexpression in multiple cancer types

A

Extensive oncology literature; TCGA pan-cancer analysis

One of the most well-characterized oncogenic receptor signals

Higher circulating IGF-1 → increased cancer risk (population)

B

Renehan et al. meta-analysis; large prospective cohorts

Population association; does not prove individual causation; relevant mechanistic signal

IGF-LR3 causes cancer in community dose/duration users

X

No human study; theoretical basis is strong

Genuinely unknown; cannot be confirmed or excluded

Protocol

Daily Dose

Duration

Timing

Notes

Conservative / First Cycle

20-30 mcg/day

4 weeks

Post-workout (training days); morning with meal (rest days)

Assess hypoglycemia sensitivity; carbs within 30 min of injection mandatory

Standard

40-60 mcg/day

4-6 weeks

Post-workout

Most commonly cited dose; above 50 mcg, diminishing returns increase faster than benefit

Higher dose (advanced)

60-80 mcg/day

4 weeks maximum

Post-workout

Non-linear benefit above ~60 mcg; significant increase in side-effect frequency; most practitioners discourage

Women's protocol

10-20 mcg/day

4 weeks

Post-workout

Women report sensitivity at lower doses; start at 10 mcg

A well-known and actively debated community practice: intramuscular injection of IGF-LR3 directly into the recently trained muscle ('site injection'), with the theory that local delivery produces preferential hypertrophy in the injected muscle. The proposed mechanism: higher local concentration at the injection site → preferential local IGF-1R activation → localized satellite cell stimulation → localized growth. The counterargument: IGF-LR3's 20-30 hour half-life means the compound distributes systemically regardless of injection site. Even if locally higher concentrations exist immediately post-IM injection, these equilibrate within hours as the compound diffuses and is absorbed into systemic circulation. The site injection 'advantage' — if any — would only occur in the short window before systemic distribution. Community consensus is divided: some experienced users swear by site injection; controlled evidence does not support a meaningful local growth advantage over SubQ. SubQ injection (abdomen or thigh) produces equivalent systemic distribution with less injection discomfort. Both routes are used; the evidence advantage for IM is Grade D-E.

Post-workout injection is the near-universal community standard for IGF-LR3 timing. The rationale: (1) exercise creates a post-workout anabolic window where muscle IGF-1R sensitivity is elevated (resistance training upregulates local IGF-1 production and receptor expression); (2) post-workout blood glucose is managed by workout carbohydrate consumption, reducing fasted hypoglycemia risk; (3) the coincidence of IGF-1R activation with elevated amino acid availability from post-workout nutrition maximizes the mTOR/protein synthesis response; (4) growth hormone naturally peaks post-workout, increasing endogenous IGF-1 — exogenous IGF-LR3 adds to this existing anabolic state. Injection before or during training increases hypoglycemia risk from the combination of exercise-induced glucose consumption and IGF-1R/IR cross-reactivity.

The 4-6 week cycle maximum reflects two compounding concerns. First, IGF-1R desensitization: receptor internalization and downregulation with continuous daily agonist exposure progressively reduces the pharmacodynamic response. Most community users report that benefits plateau and then decline between weeks 4-8, consistent with receptor downregulation. Second, organ and tissue effects: IGF-1R is expressed in visceral organs, smooth muscle of the GI tract, and connective tissues. Extended continuous activation produces measurable off-target effects including gut distension, soft tissue changes, and progressive insulin resistance. The standard cycling protocol — 4-6 weeks on, at minimum equal time off — is the community's empirical response to these phenomena. Whether the off period is sufficient to fully restore IGF-1R density, reverse insulin resistance, and reset tissue homeostasis has not been formally characterized.

Compound

Structure

Key Feature

Half-life

Primary Use Context

Key Difference from IGF-LR3

Native IGF-1 (endogenous)

70 aa

~99% IGFBP-bound; 1% free

~10-15 min (free); 12-15 hr (total)

Endogenous; also Increlex (FDA-approved for Laron syndrome)

Extensively regulated by IGFBP system; not freely available as analog

Mecasermin (Increlex)

70 aa recombinant

Same as endogenous IGF-1

Same as endogenous

FDA-approved: severe primary IGF-1 deficiency (Laron syndrome) ONLY

FDA-approved; used in deficient patients; does not share approval with IGF-LR3

IGF-LR3 (this chapter)

83 aa; Arg3 + 13-aa extension

<1% IGFBP-bound; ~100% free

~20-30 hours

Research tool; community body composition; WADA banned

Maximum IGFBP resistance; maximum free fraction; systemic; longest half-life

IGF-1 DES (des(1-3)IGF-1)

67 aa; lacks first 3 N-terminal aa

~5-10x higher IGF-1R affinity vs native IGF-1; shorter t1/2

~20-30 minutes

Site-specific injection for local effects; research tool

Shorter half-life = localized effect; IGF-LR3 is systemic. DES for local; LR3 for systemic

MGF (Mechano Growth Factor)

~24 aa C-terminal IGF-1 splice variant; various forms

IGF-1 splice variant; produced locally by muscle in response to mechanical stress

Short; highly unstable; pegylated forms extend duration

Research; AAS stacking community

Completely different mechanism and stability; community often confuses with IGF-LR3

• 'IGF-LR3 has a shorter half-life than native IGF-1': False. Native IGF-1 in blood has a 12-15 hour half-life when IGFBP-bound — but only 1% of it is free to activate receptors. Free native IGF-1 lasts 10-15 minutes. IGF-LR3 maintains ~20-30 hours of receptor accessibility. The total circulating IGF-1 half-life is longer for IGFBP-bound native IGF-1; the pharmacologically active half-life is 100-fold longer for IGF-LR3.
• 'IGF-LR3 only stimulates muscle': False. IGF-1R is expressed on virtually every cell type. IGF-LR3 stimulates IGF-1R wherever it is expressed — muscle, liver, kidney, intestinal smooth muscle, bone, fat, and tumor cells. There is no muscle selectivity.
• 'Because it doesn't suppress HPTA, IGF-LR3 is safe': Incomplete reasoning. HPTA suppression is one safety concern among many. The absence of HPTA suppression does not address hypoglycemia, organ growth, insulin resistance, or the cancer risk that is specific and well-documented for sustained IGF-1R activation. 'No HPTA suppression' ≠ 'no meaningful safety concerns.'
• 'IGF-LR3 is similar to native IGF-1, just with longer half-life': The half-life extension is mechanistically trivial compared to the pharmacokinetic consequence: near-complete elimination of IGFBP regulation. This is not a longer-lasting version of a normal physiological signal — it is a de-regulated version that bypasses the most important control system the body has for IGF-1 bioavailability.
• 'Mecasermin (Increlex) is essentially the same as IGF-LR3': Different compound. Mecasermin is native recombinant IGF-1; IGF-LR3 is an analog with eliminated IGFBP binding. Mecasermin is FDA-approved for a specific indication; IGF-LR3 is not approved for any indication. The Increlex approval does not validate IGF-LR3 safety.
• 'Site injection produces localized muscle growth': Not supported by the pharmacokinetics. With a 20-30 hour half-life, IGF-LR3 distributes systemically. Any localized concentration advantage from IM injection is transient (minutes to hours) compared to the compound's total activity window. Any growth effects are systemic, not muscle-specific.

IGF-LR3 in the community is almost exclusively used within AAS or GH secretagogue cycles, rarely as a standalone compound. The most common stacking contexts: (1) During/post-AAS cycle: Anabolic steroids elevate nitrogen retention and androgen receptor sensitivity; IGF-LR3 adds direct IGF-1R-mediated mTOR activation on top of androgen-driven protein synthesis. The theoretical synergy between androgen receptor (AR) and IGF-1R pathways is real — they converge at the mTOR level and have complementary effects on satellite cell biology. (2) With GH secretagogues (CJC-1295, ipamorelin): GH stimulates hepatic IGF-1 production; exogenous IGF-LR3 adds additional direct IGF-1R stimulation beyond what endogenous IGF-1 from the GH pulse provides. Some practitioners argue this is pharmacologically redundant if GH secretagogues are already producing adequate IGF-1 elevation; others argue the IGFBP-bypassing property of IGF-LR3 adds a distinctly different anabolic signal that endogenous IGF-1 cannot achieve due to IGFBP sequestration. (3) With BPC-157 and TB-500 for recovery: The tissue repair and angiogenic effects of BPC-157/TB-500 are mechanistically complementary to IGF-1R-mediated cellular growth signals. Whether the combination produces enhanced recovery compared to either alone has not been formally studied.

• Increased muscle fullness and pump within days of starting: consistent with IGF-1R-mediated glycogen uptake and cell swelling; real and rapid.
• Accelerated recovery between sessions: most commonly cited subjective benefit; consistent with IGF-1R anti-apoptotic and protein synthesis effects on recovering muscle.
• Gut distension ('GH gut' appearance): reported by users running higher doses or extended cycles; consistent with IGF-1R stimulation of intestinal smooth muscle; concerning as it suggests organ-level off-target effects.
• Hand and foot tingling: early sign of soft tissue growth effects from IGF-1R in connective and neural tissue; similar to acromegaly early symptoms; dose-reduce or discontinue if persistent.
• Visible hypertrophy: inconsistently reported as clearly attributable to IGF-LR3 specifically vs. the concurrent AAS or GH stack; the confounded stacking context makes causal attribution difficult.
• Hypoglycemia episodes in early use: consistent and well-reported; management requires active carbohydrate timing, not passive optimization.

IGF-LR3 quality control is more critical than for smaller, more stable peptides in this book. Key concerns: Sequence confirmation requires mass spectrometry — not just HPLC. The 83-amino acid sequence with its modified terminus has specific mass that distinguishes it from shorter IGF-1 variants or synthesis failures. A product that passes HPLC purity (no major impurity peaks) might still contain the wrong analog (e.g., IGF-1 DES instead of LR3, or truncated fragments) that looks similar on purity testing. Verify MW. Endotoxin testing is critical — the injection of contaminated protein solutions causes fever, inflammation, and systemic effects that are sometimes misattributed to pharmacological activity. Temperature and acidity of reconstitution: use 0.1% acetic acid or dilute HCl rather than bacteriostatic water alone for optimal stability; refrigerate immediately at 2-8°C; use within 2-4 weeks of reconstitution; do not shake.

Francis GL, Ross M, Ballard FJ, Milner SJ, Senn C, McNeil KA, Wallace JC, King R, Wells JR. (1992). Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. J Mol Endocrinol. 8(3):213-23. PMID 1386427. [The original IGF-LR3 paper — characterizes the Arg3 substitution and N-terminal extension; demonstrates IGFBP binding reduction and biological potency enhancement in cell culture. The foundational reference for the entire IGF-LR3 literature.]

Tomas FM, Knowles SE, Owens PC, Read LC, Chandler CS, Gargosky SE, Wallace JC, Ballard FJ. (1996). Increased efficiency of IGF-I action due to the addition of the Arg3 modification and an N-terminal extension. [Demonstrates 1.5-2x greater potency vs native IGF-1 in catabolic animal models; key pharmacological potency reference.]

LeRoith D, Roberts CT Jr. (2003). The insulin-like growth factor system and cancer. Cancer Letters. 195(2):127-137. [Key review establishing IGF-1R's role in tumor promotion, anti-apoptosis, and cancer progression.]

Pollak M. (2008). Insulin and insulin-like growth factor signalling in neoplasia. Nature Reviews Cancer. 8(12):915-928. [Comprehensive review of IGF-1R pathway in cancer; the primary reference for understanding why sustained IGF-1R activation is oncologically concerning.]

Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. (2004). Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 363(9418):1346-1353. [Meta-analysis establishing epidemiological IGF-1 and cancer risk associations: colorectal OR 1.49; premenopausal breast OR 1.65; prostate OR 1.49.]

Musaro A, McCullagh K, Paul A, Houghton L, Dobrowolny G, Molinaro M, Barton ER, Sweeney HL, Rosenthal N. (2001). Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nature Genetics. 27(2):195-200. [IGF-1 overexpression in aging mouse muscle prevents atrophy and accelerates regeneration; key preclinical evidence that IGF-1 axis drives muscle growth.]

Bodine SC, Stitt TN, Gonzalez M, Kline WO, Stover GL, Bauerlein R, Zlotchenko E, Scrimgeour A, Lawrence JC, Glass DJ, Yancopoulos GD. (2001). Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nature Cell Biology. 3(11):1014-1019. [Establishes PI3K/Akt/mTOR as the central hypertrophy pathway downstream of IGF-1R; the mechanistic basis for IGF-LR3's anabolic rationale.]

• Active malignancy of any type: absolute contraindication. No exception.
• History of malignancy with IGF-1R-sensitive histology (breast, prostate, colorectal, lung): absolute contraindication without oncologist clearance.
• No cancer history; seeking body composition benefit: the compound has no controlled human evidence for the application; WADA-banned; the cancer risk is mechanistically grounded and poorly characterized for community doses; hypoglycemia requires active management. These are the informed consent elements. The individual decision with this information is each person's own.
• Athletes in tested sports: WADA S2 banned at all times. Absolute prohibition.

• 'No HPTA suppression = safe': IGF-LR3 has a specific, mechanistically grounded cancer risk that has nothing to do with HPTA. Safety is not defined solely by testosterone axis effects.
• 'The IGF-1R pathways prove it builds muscle in humans': mechanism ≠ human outcome evidence. The pathway exists; the human controlled trial demonstrating meaningful muscle gain in healthy adults does not.
• 'I can limit cancer risk by using short cycles': this is a reasonable harm reduction approach but not a safety guarantee. Undetected pre-malignant lesions respond to IGF-1R activation at the cellular level; there is no known minimum cycle length that is demonstrably safe.

— End of IGF-LR3 —

THE PEPTIDE BIBLE | IGF-LR3 | For Research & Educational Purposes Only